Monday, 22 April 2024

[the_ad_group id="2845"]

Business News

Buy Rating Affirmed Amid Arcutis’ Strong Defense Against Generic Competition – TipRanks Financial Blog

Provention Bio price target raised to $30 from $24 at Chardan

[the_ad id="21475"]


Arcutis Biotherapeutics (ARQTResearch Report), the Healthcare sector company, was revisited by a Wall Street analyst on April 1. Analyst Uy Ear from Mizuho Securities maintained a Buy rating on the stock and has a $17.00 price target.

Uy Ear has given his Buy rating due to a combination of factors, primarily focusing on the complexities surrounding the potential approval of a generic competitor to Arcutis Biotherapeutics’ Zoryve Cream. He points out that the differences between the generic cream developed by Padagis and Arcutis’ Zoryve could present significant hurdles in obtaining FDA approval. Historically, complex generics, particularly topical ones, have struggled to clear the FDA’s rigorous approval process, and any additional differences only compound that challenge.
Moreover, Ear emphasizes the strategic legal move by Arcutis to file a lawsuit against Padagis, which is expected to result in a 30-month stay on FDA final approval for the generic version, effectively protecting Zoryve until late October 2026. This stay is crucial for Arcutis as it ensures market exclusivity for an extended period, thereby safeguarding revenue from one of its key products. Additionally, the existence of multiple patents extending into 2037 fortifies Arcutis’ position, making it a solid investment in Ear’s view.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Arcutis Biotherapeutics (ARQT) Company Description:

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.

Click Here to Read the Full Original Article at TipRanks Financial Blog…


[the_ad id="21476"]